<DOC>
	<DOCNO>NCT01205880</DOCNO>
	<brief_summary>This investigator-blinded study design ass whether order application affect efficacy combination treatment Clobex® Spray ( clobetasol propionate ) Vecitcal® ( calcitriol ) Ointment plaque psoriasis .</brief_summary>
	<brief_title>Study Evaluate Vectical Combination With Clobex Spray Treatment Plaque Psoriasis</brief_title>
	<detailed_description>This investigator-blinded , bilateral comparison study . A total 12 subject mild moderate plaque psoriasis enrol study , least 10 subject complete 4 week trial . These 12 subject receive combination therapy Clobex® Spray Vectical® Ointment treat psoriatic lesion ( except scalp , face , groin , axillae intertriginous area ) . Half subject first apply Clobex® Spray follow Vectical ointment lesion right side body , Vectical® Ointment first follow Clobex® Spray lesion leave side body . The half subject first apply Clobex® Spray follow Vectical® Ointment lesion leave side body , Vectical® Ointment first follow Clobex® Spray lesion right side body . Treatment applied twice daily 4 week . One target area side subject 's body choose target lesion assessment . All subject consent prior study evaluations/procedures . Study evaluation include Target Lesion Severity Score ( TLSS ) photography perform Baseline/Day 0 , week 2 week 4 .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Clobetasol</mesh_term>
	<criteria>1 . Subjects must least 18 year age good general health confirm medical history . 2 . Females childbearing potential must negative urine pregnancy test Baseline/Day 0 must agree use adequate birth control method entire study ( barrier method { condom , diaphragm } ; hormonal contraceptive { birth control pill , implant [ Norplant ] injection [ DepoProvera ] } ; intrauterine device { IUD } ; abstinence { sexual activity } ) . 3 . Subjects must diagnose plaque psoriasis affect &lt; 20 % body surface area , least one discreet plaque side body ( exclude face , scalp , groin , axillae intertriginous area ) . 4 . Subjects must least 2 lesion suitable evaluate response test agent ( one right side one leave side body ) . The severity disease target lesion Baseline/Day 0 must rat least 2 ( Mild ) key psoriasis characteristic ( scale , erythema , plaque elevation ) . 5 . Subjects must able understand requirement study abide restriction return require examination . 1 . Female subject pregnant , nurse plan pregnancy study . 2 . Subjects know hypersensitivity component test medication . 3 . Subjects nonplaque psoriasis ( e.g . guttate , erythrodermic ) relate disease classify plaque psoriasis . 4 . Subjects whose psoriasis involve scalp , face , groin , axilla , and/or intertriginous area . 5 . Subjects surface area involvement large ( &gt; 20 % BSA ) would require 59 ml/week ( 50 g/week ) Clobex® spray and/or 200 g/week Vectical® ointment . 6 . Subjects require medication ( topical systemic ) may affect course disease study period determine study investigator . 7 . Subjects use biologics systemic treatment ( e.g . immunosuppressant , acitretin ) psoriasis within 12 week enter study . 8 . Subjects use systemic corticosteroid within 28 day enter study 9 . Subjects use topical corticosteroid topical therapy ( emollient ) target area location within 2 week enter study 10 . Subjects use phototherapy ( UVB , PUVA ) within 4 week enter study . 11 . Subjects overt preexist telangiectasias skin atrophy intend treatment site ( target area ) . 12 . Subjects intakes 2,000 IU/day ( 50 mcg/day ) vitamin D ( tolerable upper intake level ) and/or 1,000 mg/day calcium ( base Dietary Reference Intakes develop Institute Medicine National Academy Sciences ) . 13 . Subjects participate another investigational drug device research study ( target area ) within 30 day enrollment . 14 . Subjects use medication disease judgment investigator interfere conduct interpretation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>combination treatment</keyword>
	<keyword>topical corticosteroid</keyword>
	<keyword>vitamin D analogue</keyword>
	<keyword>clobex</keyword>
	<keyword>vectical</keyword>
	<keyword>clobetasol</keyword>
	<keyword>calcitriol</keyword>
</DOC>